Innovations in biotherapeutic medicines are advancing at an unprecedented pace and offer great promise for improving outcomes for patients.
As we approach our 200th anniversary year in 2020, I am proud to announce a major milestone in USP’s publication history, the conclusion of the USP–NF printed product.
What happens when patients who receive a trusted treatment start experiencing adverse reactions? And what can be done to help prevent it from reoccurring?
Patients, their families and health care providers alike care about the quality of their medicines. For nearly 200 years, USP has contributed to the quality of medicines by providing publicly-available standards.
For patients needing a bone marrow or stem cell transplant, successful treatment often depends on finding a viable transplant sample with the right amount of hematopoietic stem cells (HSCs) to rebuild the patient’s immune system.
January 1 was more than just the start of a new year for USP in 2018. It was the implementation date of two new standards designed to safeguard the global drug supply from potentially toxic impurities – mercury, cadmium, arsenic, and lead, for example.
As personalized therapies have become a reality rather than a distant promise, the tools needed to ensure the quality of these medicines grow increasingly important.
Show 11 More